Your browser doesn't support javascript.
loading
Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.
Feng, Wei; Chen, Xi; Guan, Shao-Xing; Ruan, Hong-Lian; Huang, Yan; Zhang, Hui-Zhen; Yang, Yun-Peng; Fang, Wen-Feng; Zhao, Hong-Yun; Zhuang, Wei; Xin, Shuang; Chen, You-Hao; Wang, Fei; Gao, Yue; Huang, Min; Wang, Xue-Ding; Zhang, Li.
Afiliação
  • Feng W; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
  • Chen X; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.
  • Guan SX; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
  • Ruan HL; School of Public Health, Guangzhou Medical University, Guangzhou, 510000, China.
  • Huang Y; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.
  • Zhang HZ; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
  • Yang YP; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.
  • Fang WF; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.
  • Zhao HY; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.
  • Zhuang W; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
  • Xin S; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.
  • Chen YH; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
  • Wang F; Ersha Department of Pharmacy, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
  • Gao Y; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
  • Huang M; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China. huangmin@mail.sysu.edu.cn.
  • Wang XD; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China. wangxd@mail.sysu.edu.cn.
  • Zhang L; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, China. zhangli@sysucc.org.cn.
Acta Pharmacol Sin ; 43(7): 1857-1864, 2022 Jul.
Article em En | MEDLINE | ID: mdl-34737420
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article